Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 865
- 试验地点
- 5
- 主要终点
- Overall survival
研究概览
简要总结
The purpose of this study is to validate TNM-Immunoscore in resected non-small cell lung cancer.
详细描述
The main aim is to validate the most promising T-cell marker candidates from earlier studies in a prospective multicenter study to establish a prognostic TNM-Immunoscore.
The investigators will include around 1000 stage I-IIIA patients from various centers in Scandinavia. The investigators will also collect demographic and clinicopathological data, blood and tissues in a database and biobank. Candidate T-cell markers will be analyzed by immunohistochemistry for validation and by other methods for exploration of their impact on prognosis
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •resectable NSCLC
- •Age 18 and above
- •no other malignancy last 5 years
- •informed consent
排除标准
- •multiple tumor foci
- •preoperative chemo- or radiotherapy
- •non-NSCLC histology
- •no tissue available for study
- •metastasis
结局指标
主要结局
Overall survival
时间窗: 5 year follow-up
Overall survival in the 1) overall population and in the 2) squamous cell carcinoma and 3) adenocarcinoma subgroups.
次要结局
- TTR(5 year follow-up)
- Disease-specific survival(5 year follow-up)